美国唐氏综合征人群COVID-19疫苗接种率研究
本研究基于田纳西州医疗补助计划中1995-2021年出生且在Vanderbilt大学医学中心就诊的唐氏综合征患者,评估COVID-19疫苗接种率及相关因素。438人中仅35%至少接种一剂,91%完成基础系列;年轻年龄和无流感疫苗接种史与接种率降低强相关。
要点
- 唐氏综合征患者COVID-19疫苗总体接种率低,仅35%至少接种一剂。
- 年轻年龄和无流感疫苗接种史是未接种或未完成基础系列的强相关因素。
- 可利用年龄和流感疫苗接种史识别接种风险人群,指导针对性策略。
核心结论
- 仅三分之一唐氏综合征患者接种任何COVID-19疫苗,表明该高风险人群接种率低。
研究设计与样本
- 研究纳入1995-2021年出生、参加田纳西州医疗补助计划且在Vanderbilt大学医学中心至少就诊一次的唐氏综合征患者,共438人。
- 通过田纳西州免疫信息系统确认COVID-19疫苗接种日期和类型,采用多变量逻辑回归分析相关因素。
主要发现
- 438人中,95人(22%)在16岁及以上首次符合接种条件,88人(20%)在12-15岁,187人(43%)在5-11岁,68人(16%)在6个月-4岁。
- 总体152人(35%)至少接种一剂COVID-19疫苗,其中138人(91%)完成基础系列。
- 年轻年龄和无流感疫苗接种史(从未接种或疫情期间未接种)与接种COVID-19疫苗或完成基础系列的可能性降低强相关。
临床怎么用
- 可利用年龄和流感疫苗接种史等 readily available 信息识别未接种风险较高的唐氏综合征患者。
- 针对年轻及无流感疫苗接种史者制定靶向策略以提高COVID-19疫苗覆盖率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Individuals with Down syndrome are at increased risk for severe disease from acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, making them a priority group for COVID-19 vaccination. Data on vaccine uptake and factors associated with vaccination are needed to inform strategies to improve uptake in this vulnerable population. OBJECTIVE: To evaluate COVID-19 vaccine uptake and identify factors associated with vaccination among individuals with Down syndrome. METHODS: The population included individuals with Down syndrome born during 1995-2021 and enrolled in the Tennessee Medicaid Program during the COVID-19 pandemic. We limited the study population to individuals who sought care at the Vanderbilt University Medical Center at least once between six months after their initial eligibility for the COVID-19 vaccine and October 1, 2024. Date and type of COVID-19 vaccine receipt were ascertained from the Tennessee Immunization Information System. Demographic and clinical characteristics associated with COVID-19 vaccine uptake and completion of the primary series were analyzed using multivariable logistic regression. RESULTS: Among 438 individuals with Down syndrome, 95 (22%), 88 (20%), 187 (43%), and 68 (16%) first became eligible for COVID-19 vaccine at age 16+, 12-15, 5-11, and 6 months-4 years of age, respectively. Overall, 152 (35%) received at least one dose of the COVID-19 vaccine; of these, 138 (91%) completed the primary series. Younger age and lack of influenza vaccination history-either never or during the pandemic-were strongly associated with a reduced likelihood of receiving COVID-19 vaccine or completing the primary series. CONCLUSIONS: Only one-third of individuals with Down syndrome received any COVID-19 vaccine, indicating low uptake in this high-risk population. Readily available information on individuals' age and influenza vaccination history may help identify individuals at increased risk of remaining unvaccinated, thereby informing targeted strategies to improve coverage and reduce COVID-19-related morbidity.
引用
- Nian H, Ding T, Lee RL, et al. COVID-19 vaccine uptake among individuals with Down syndrome in the Unites States. Vaccine. 2026. PMID: 42691822. doi:10.1016/j.vaccine.2026.129128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。